• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>FTI Consulting

FTI Consulting

FTI Consulting Inc FCN

Last Price$32.49Day Change (%)-0.79%
Open Price$32.61Day Change ($)-0.26
Day Range32.37–32.8852-Week Range31.65–47.12

As of Thu 8/17/2017 5:53:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Orosur Mining Inc Announces Oversubscribed Conditional Subscription to Raise Approximately US$3.2 Million

    Orosur Mining Inc Announces Oversubscribed Conditional Subscription to Raise Approximately US$3.2 Million

  2. Janus Henderson Reports Second Quarter 2017 Diluted EPS of $0.28, or $0.68 on a Pro Forma Adjusted Basis

    Janus Henderson Reports Second Quarter 2017 Diluted EPS of $0.28, or $0.68 on a Pro Forma Adjusted Basis

  3. Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point

    Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point

  4. Venezuelan Default Fears Rise With Billions in Debt Coming Due Soon -- Update

    Venezuelan Default Fears Rise With Billions in Debt Coming Due Soon -- Update

  5. Mainstay Medical International plc (“Mainstay” or the “Company”): Total Voting Rights

    Mainstay Medical International plc (“Mainstay” or the “Company”): Total Voting Rights

  6. SDL plc Interim results for the six months ended 30 June 2017

    SDL plc Interim results for the six months ended 30 June 2017

  7. Alaska Communications Appoints Shawn O’Donnell to Its Board of Directors

    Alaska Communications Appoints Shawn O’Donnell to Its Board of Directors

  8. Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases

    Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases

  9. Dassault Systèmes Delivers Q2 Software Revenue and EPS at the High-end of its Objectives and Signs with Boeing a New and Expanded Historic Partnership Agreement

    Dassault Systèmes Delivers Q2 Software Revenue and EPS at the High-end of its Objectives and Signs with Boeing a New and Expanded Historic Partnership Agreement

  10. Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma

    Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma

12345

©2017 Morningstar Advisor. All right reserved.